CN1529600A - Nk-1受体拮抗剂在改变狗、猫和马的不需要行为中的用途 - Google Patents

Nk-1受体拮抗剂在改变狗、猫和马的不需要行为中的用途 Download PDF

Info

Publication number
CN1529600A
CN1529600A CNA028141873A CN02814187A CN1529600A CN 1529600 A CN1529600 A CN 1529600A CN A028141873 A CNA028141873 A CN A028141873A CN 02814187 A CN02814187 A CN 02814187A CN 1529600 A CN1529600 A CN 1529600A
Authority
CN
China
Prior art keywords
amino
methyl
benzyl
methoxybenzyl
phenylpiperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028141873A
Other languages
English (en)
Chinese (zh)
Inventor
��������S�����ʿ�
布赖恩·S·布朗克
A��ϣ����
玛丽·A·希克曼
R
卡罗琳·R·基尔罗伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1529600A publication Critical patent/CN1529600A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA028141873A 2001-07-20 2002-07-15 Nk-1受体拮抗剂在改变狗、猫和马的不需要行为中的用途 Pending CN1529600A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30669201P 2001-07-20 2001-07-20
US60/306,692 2001-07-20

Publications (1)

Publication Number Publication Date
CN1529600A true CN1529600A (zh) 2004-09-15

Family

ID=23186426

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028141873A Pending CN1529600A (zh) 2001-07-20 2002-07-15 Nk-1受体拮抗剂在改变狗、猫和马的不需要行为中的用途

Country Status (13)

Country Link
US (1) US20030139443A1 (enExample)
EP (1) EP1411946A1 (enExample)
JP (1) JP2005504029A (enExample)
KR (1) KR20040029375A (enExample)
CN (1) CN1529600A (enExample)
CA (1) CA2448722A1 (enExample)
CZ (1) CZ200434A3 (enExample)
HU (1) HUP0401154A2 (enExample)
IL (1) IL158990A0 (enExample)
PL (1) PL367944A1 (enExample)
SK (1) SK252004A3 (enExample)
WO (1) WO2003009848A1 (enExample)
ZA (1) ZA200308991B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100834232B1 (ko) * 2004-01-30 2008-05-30 화이자 프로덕츠 인크. 액체 투여형용 베타-시클로덱스트린을 사용하는 다수회투여 제형을 얻기 위한 항균 방부제
JP2007519701A (ja) 2004-01-30 2007-07-19 ファイザー・プロダクツ・インク 麻酔回復を改善するためのｎｋ−１受容体拮抗剤
MXPA06012504A (es) * 2004-04-30 2006-12-15 Schering Corp Moduladores del receptor neuropeptido.
CN114403042A (zh) * 2021-12-13 2022-04-29 深圳先进技术研究院 一种大动物焦虑症动物模型

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
FR2677361A1 (fr) * 1991-06-04 1992-12-11 Adir Nouveaux peptides et pseudopeptides, derives de tachykinines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE122006000066I2 (de) * 1991-05-31 2007-12-06 Pfizer Chinuclidinderivate
BR9206161A (pt) * 1991-06-20 1995-10-31 Pfizer Derivados fluoroalcoxibenzilamino de heterociclos contendo nitrogénio
US5688806A (en) * 1993-03-04 1997-11-18 Pfizer Inc. Spiroazacyclic derivatives as substance P antagonists
EP0623344B1 (fr) * 1993-05-04 2000-07-26 Ceva Sante Animale Utilisation de la Sélégiline en médecine vetérinaire
IL109646A0 (en) * 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0719266A1 (en) * 1993-09-17 1996-07-03 Pfizer Inc. Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds
US6083943A (en) * 1993-09-17 2000-07-04 Pfizer Inc Substituted azaheterocyclecarboxylic acid
US5854262A (en) * 1993-10-07 1998-12-29 Pfizer Inc. Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
PE45195A1 (es) * 1994-03-03 1996-01-17 Boehringer Ingelheim Kg Derivado de aminoacido, procedimiento para su preparacion y composicion farmaceutica que lo contiene
US5607936A (en) * 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists
ATE279406T1 (de) * 1995-01-12 2004-10-15 Glaxo Group Ltd Piperidinderivate mit tachykinin-antagonistischer wirkung
US5990125A (en) * 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer
DE69736390T2 (de) * 1996-10-07 2007-07-26 Merck Sharp & Dohme Ltd., Hoddesdon Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
DE69710921T2 (de) * 1996-12-19 2002-09-19 Aventis Pharmaceuticals Inc., Bridgewater Heterocyclische substituierte pyrrolidinamid-derivate
US6156749A (en) * 1997-12-01 2000-12-05 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating movement disorders
JP4669095B2 (ja) * 1999-07-19 2011-04-13 太陽化学株式会社 ペットの問題行動抑制組成物
CA2280309C (en) * 1999-08-13 2007-05-08 William Norton Milgram Use of adrafinil to treat behavioral problems in aged canines
CA2324813A1 (en) * 1999-11-10 2001-05-10 Susan Beth Sobolov-Jaynes Combination treatment for depression and anxiety
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety

Also Published As

Publication number Publication date
CZ200434A3 (cs) 2005-02-16
SK252004A3 (sk) 2005-03-04
PL367944A1 (en) 2005-03-07
US20030139443A1 (en) 2003-07-24
JP2005504029A (ja) 2005-02-10
CA2448722A1 (en) 2003-02-06
HUP0401154A2 (hu) 2004-10-28
ZA200308991B (en) 2004-11-19
KR20040029375A (ko) 2004-04-06
EP1411946A1 (en) 2004-04-28
WO2003009848A1 (en) 2003-02-06
IL158990A0 (en) 2004-05-12

Similar Documents

Publication Publication Date Title
US11124514B2 (en) Compositions and methods
CN1132625A (zh) 用于治疗呕吐的nk-1爱体拮抗剂和5ht3受体拮抗剂
CN1642547A (zh) 治疗中枢神经系统障碍的药物组合物和方法
JP7306614B2 (ja) トラジピタントを用いた胃腸疾患の治療方法
US20160058762A1 (en) Combinations of serotonin receptor agonists for treatment of movement disorders
CN1402637A (zh) 用于治疗cns疾病的吡咯烷乙酰胺衍生物或者其组合物
CN1494907A (zh) 治疗疼痛的药物组合物
EP3897641B1 (en) Treatment of movement disorders
US20210161880A1 (en) Methods for treating dementia related psychosis
TW201247200A (en) New association between 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benzamide and an acetylcholinesterase inhibitor, and pharmaceutical compositions containing it
JP2009518423A (ja) 統合失調症の副作用および陰性症状を治療するためのｃｂ１アンタゴニストの使用
EP3890735A1 (en) Method of treatment with tradipitant
JP2005533080A (ja) Ｎｋ−１およびｎｋ−３アンタゴニストによる鬱病および不安症の併用療法
CN1529600A (zh) Nk-1受体拮抗剂在改变狗、猫和马的不需要行为中的用途
HK1065256A (en) Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses
CN1285742A (zh) 用于治疗阿尔茨海默氏型老年性痴呆的活性组分的组合
AU2002317436A1 (en) Use of NK-1 receptor antagonists to modify unwanted behaviour in dogs, cats and horses
JP2005504029A5 (enExample)
CN1247578C (zh) 含有2－芳基－8－氧化二氢嘌呤衍生物作为活性成分的痴呆症治疗剂
CN1386504A (zh) 用于抑郁症和焦虑的联合治疗
CN1319532C (zh) N－(吲哚羰基)哌嗪衍生物的用途
CN1555259A (zh) 取代的氨甲基苯并二氢吡喃在运动障碍和治疗锥体束外运动障碍药物引发的不利影响的治疗中的用途
CN1761467A (zh) 2－取代－吡啶－甲胺衍生物在制备用于治疗神经性和心理性慢性疼痛症状的药物的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1065256

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1065256

Country of ref document: HK